{"id":755869,"date":"2023-05-08T08:08:44","date_gmt":"2023-05-08T12:08:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/"},"modified":"2023-05-08T08:08:44","modified_gmt":"2023-05-08T12:08:44","slug":"ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/","title":{"rendered":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BEDFORD, Mass., May  08, 2023  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc.\u00a0(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY.<\/p>\n<p>In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their JMP representative.<\/p>\n<p>A live webcast of the fireside chat can be accessed by visiting the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yjBtMQTHeiptgblKVnnmO9aZp6oLXVqex1myz4IrG2w3smrx-4WlZ9FjxxarhSVDcMCagbGByL92asYhPdqrqwEFH9Gs1qvMOC1J7AXmXMc=\" rel=\"nofollow noopener\" target=\"_blank\">investors.ocutx.com<\/a>.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc. <\/strong>\n      <\/p>\n<p>Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix\u2019s first commercial drug product, DEXTENZA<sup>\u00ae<\/sup>, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix\u2019s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, both of which have completed Phase 2 clinical trials.<\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Ocular Therapeutix<br \/>Donald Notman<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Fs13SnQjzTRiIQtpLc6uhjW_xskO2PYJUrrG9M1kf1ZtVImsdI3-DkHQ--OhU-dQC7tSSzYkuXNMwYnAsiSSQ==\" rel=\"nofollow noopener\" target=\"_blank\">dnotman@ocutx.com<\/a><\/p>\n<p>or<\/p>\n<p>ICR Westwicke <br \/>Chris Brinzey<br \/>Managing Director<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MX-y1ejcobWK36sytv33Q4lTHxtPgTPTlj5S-ghnlc3WSK01vDErmZL9Zp6Hq7_3KgC1cZWgCzd6rfsWTaSEZcUhK1roIHYowNHMyqMqMUkhd9AAVA70t4Yxc_eXidGD\" rel=\"nofollow noopener\" target=\"_blank\">chris.brinzey@westwicke.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDQxYmFjMWEtOTM4ZS00MDU2LWEyMWQtN2NiM2U3MmQyODQ4LTEwMjI2Mjk=\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc.\u00a0(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their JMP representative. A live webcast of the fireside chat can be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc.\u00a0(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their JMP representative. A live webcast of the fireside chat can be &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T12:08:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference\",\"datePublished\":\"2023-05-08T12:08:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\",\"datePublished\":\"2023-05-08T12:08:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","og_description":"BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc.\u00a0(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their JMP representative. A live webcast of the fireside chat can be &hellip; Continue reading \"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T12:08:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference","datePublished":"2023-05-08T12:08:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/","name":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=","datePublished":"2023-05-08T12:08:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzM2MCM1NTc4ODk0IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Present at the JMP Securities Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}